$USPH
U S PHYSICAL THERAPY INC /NV

2023 Q1 Form 10-K Financial Statement

#000114036123009198 Filed on February 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $148.5M $141.2M $553.1M
YoY Change 12.76% 8.74% 11.74%
Cost Of Revenue $117.7M $113.4M $441.1M
YoY Change 11.93% 10.44% 16.76%
Gross Profit $30.86M $27.83M $112.0M
YoY Change 16.06% 2.35% -4.4%
Gross Profit Margin 20.78% 19.71% 20.25%
Selling, General & Admin $13.86M $11.93M $46.11M
YoY Change 19.93% 11.26% -0.91%
% of Gross Profit 44.91% 42.85% 41.16%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.788M $3.793M $14.74M
YoY Change -0.94% 23.47% 27.19%
% of Gross Profit 12.28% 13.63% 13.16%
Operating Expenses $13.86M $11.93M $46.11M
YoY Change 19.93% 11.26% -0.91%
Operating Profit $17.00M $15.91M $56.80M
YoY Change 13.08% -3.45% -19.6%
Interest Expense -$2.222M -$1.978M -$3.745M
YoY Change 1333.55% 5105.26% 493.5%
% of Operating Profit -13.07% -12.44% -6.59%
Other Income/Expense, Net -$2.602M -$256.0K -$1.230M
YoY Change -680.8% -148.29%
Pretax Income $14.40M $4.560M $55.57M
YoY Change -7.0% -75.2% -24.08%
Income Tax $2.969M $1.212M $12.16M
% Of Pretax Income 20.62% 26.58% 21.89%
Net Earnings $7.410M -$145.0K $32.16M
YoY Change -15.79% -101.42% -21.24%
Net Earnings / Revenue 4.99% -0.1% 5.81%
Basic Earnings Per Share $0.58 $2.25
Diluted Earnings Per Share $0.58 -$0.01 $2.25
COMMON SHARES
Basic Shares Outstanding 13.03M 13.00M 12.99M
Diluted Shares Outstanding 13.03M 12.99M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.60M $31.59M $31.59M
YoY Change 34.57% 10.6% 10.6%
Cash & Equivalents $32.61M $31.59M $31.59M
Short-Term Investments
Other Short-Term Assets $10.73M $11.07M $10.37M
YoY Change 165.5% 164.57% 189.34%
Inventory
Prepaid Expenses
Receivables $56.65M $51.93M $68.61M
Other Receivables $0.00 $0.00 $700.0K
Total Short-Term Assets $117.8M $111.3M $111.3M
YoY Change 22.9% 16.92% 16.92%
LONG-TERM ASSETS
Property, Plant & Equipment $24.64M $24.75M $127.8M
YoY Change -79.19% 7.7% 6.99%
Goodwill $501.3M $494.1M
YoY Change 12.99% 13.67%
Intangibles $109.0M $108.8M
YoY Change 19.06% 25.9%
Long-Term Investments $12.16M $12.13M $12.13M
YoY Change -2.11% -0.69% -0.69%
Other Assets $2.593M $4.149M $4.149M
YoY Change 31.49% 162.93% 162.93%
Total Long-Term Assets $750.3M $746.9M $746.9M
YoY Change 12.32% 14.16% 14.16%
TOTAL ASSETS
Total Short-Term Assets $117.8M $111.3M $111.3M
Total Long-Term Assets $750.3M $746.9M $746.9M
Total Assets $868.1M $858.2M $858.2M
YoY Change 13.65% 14.51% 14.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.233M $6.504M $6.504M
YoY Change -34.63% 0.51% 0.51%
Accrued Expenses $45.22M $37.41M $71.12M
YoY Change -11.54% -18.14% -3.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.730M $7.863M $7.863M
YoY Change 867.46% 847.35% 847.35%
Total Short-Term Liabilities $90.83M $85.49M $85.49M
YoY Change 2.04% 2.41% 2.41%
LONG-TERM LIABILITIES
Long-Term Debt $182.7M $175.8M $175.8M
YoY Change 49.58% 49.53% 49.53%
Other Long-Term Liabilities $13.87M $13.03M $90.96M
YoY Change -81.85% 77.39% 11.57%
Total Long-Term Liabilities $196.6M $188.9M $266.8M
YoY Change 60.94% 51.17% 33.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $90.83M $85.49M $85.49M
Total Long-Term Liabilities $196.6M $188.9M $266.8M
Total Liabilities $384.4M $373.6M $542.4M
YoY Change -16.96% 25.79% 19.51%
SHAREHOLDERS EQUITY
Retained Earnings $234.8M $232.9M
YoY Change 3.81%
Common Stock $152.0K $152.0K
YoY Change 0.66%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M $31.63M
YoY Change 0.0%
Treasury Stock Shares $2.215M $2.215M
Shareholders Equity $318.1M $315.8M $315.8M
YoY Change
Total Liabilities & Shareholders Equity $868.1M $858.2M $858.2M
YoY Change 13.65% 14.51% 14.51%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $7.410M -$145.0K $32.16M
YoY Change -15.79% -101.42% -21.24%
Depreciation, Depletion And Amortization $3.788M $3.793M $14.74M
YoY Change -0.94% 23.47% 27.19%
Cash From Operating Activities $11.35M $17.30M $58.54M
YoY Change -2.58% 8.76% -23.39%
INVESTING ACTIVITIES
Capital Expenditures $2.059M $958.0K $8.248M
YoY Change -181.45% -143.45% -200.57%
Acquisitions $5.796M $59.79M
YoY Change -48.44% -31.14%
Other Investing Activities -$10.62M -$42.43M -$73.02M
YoY Change -20.83% -45.37% -37.02%
Cash From Investing Activities -$12.68M -$43.39M -$81.27M
YoY Change -20.47% -45.68% -34.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $938.0K $1.875M
YoY Change
Cash From Financing Activities 2.343M 19.77M 25.76M
YoY Change -5548.84% -73.05% -40.62%
NET CHANGE
Cash From Operating Activities 11.35M 17.30M 58.54M
Cash From Investing Activities -12.68M -43.39M -81.27M
Cash From Financing Activities 2.343M 19.77M 25.76M
Net Change In Cash 1.011M -6.320M 3.027M
YoY Change -123.31% -167.38% -169.57%
FREE CASH FLOW
Cash From Operating Activities $11.35M $17.30M $58.54M
Capital Expenditures $2.059M $958.0K $8.248M
Free Cash Flow $9.290M $16.34M $50.29M
YoY Change -34.47% -9.77% -40.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts
FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Allowance for Credit Losses</div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">The Company determines allowances for credit losses based on the specific agings and payor classifications at each clinic. The provision for credit losses is included in operating costs in the consolidated statements of income. Patient accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for credit losses, includes only those amounts the Company estimates to be collectible.</div>
CY2021Q4 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
117587000
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Registrant Name
EntityRegistrantName
U S PHYSICAL THERAPY INC /NV
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000885978
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Auditor Firm
AuditorFirmId
248
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
1-11151
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0364866
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1300 WEST SAM HOUSTON PARKWAY SOUTH
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
HOUSTON
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77042
CY2022 dei City Area Code
CityAreaCode
713
CY2022 dei Local Phone Number
LocalPhoneNumber
297-7000
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $.01 par value
CY2022 dei Trading Symbol
TradingSymbol
USPH
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
774000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13028845
CY2022 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2022 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
21303000
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
553144000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
495022000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
422969000
CY2022 us-gaap Labor And Related Expense
LaborAndRelatedExpense
319191000
CY2021 us-gaap Labor And Related Expense
LaborAndRelatedExpense
278469000
CY2020 us-gaap Labor And Related Expense
LaborAndRelatedExpense
235629000
CY2022 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
116381000
CY2021 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
94066000
CY2020 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
88267000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5548000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5305000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4623000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
441120000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
377840000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
328519000
CY2022 us-gaap Gross Profit
GrossProfit
112024000
CY2021 us-gaap Gross Profit
GrossProfit
117182000
CY2020 us-gaap Gross Profit
GrossProfit
94450000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9112000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46111000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46533000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42037000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
56801000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
70649000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
52413000
CY2022 usph Relief Funds
ReliefFunds
0
CY2021 usph Relief Funds
ReliefFunds
4597000
CY2020 usph Relief Funds
ReliefFunds
13501000
CY2022 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
0
CY2021 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
0
CY2020 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
1091000
CY2022 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2021 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2635000
CY2020 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2022 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
CY2021 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
1216000
CY2020 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
CY2022 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
2520000
CY2021 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
CY2020 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
0
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1175000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
112000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
859000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
199000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
142000
CY2022 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
-5000
CY2021 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
0
CY2020 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
0
CY2022 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
5779000
CY2021 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
942000
CY2020 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
1634000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1230000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2547000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13100000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55571000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
73196000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
65513000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12164000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15272000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13022000
CY2022 us-gaap Profit Loss
ProfitLoss
43407000
CY2021 us-gaap Profit Loss
ProfitLoss
57924000
CY2020 us-gaap Profit Loss
ProfitLoss
52491000
CY2022 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
6902000
CY2021 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
11358000
CY2020 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
11175000
CY2022 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
4347000
CY2021 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
5735000
CY2020 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
6122000
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11249000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17093000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
17297000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
32158000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
40831000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
35194000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.25
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.41
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.41
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.48
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.48
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12985000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12985000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12898000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12898000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12835000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12835000
CY2022 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.64
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.46
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.32
CY2022 usph Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent
0.2555
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
241701000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2020 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-3415000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7917000
CY2020 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
486000
CY2020 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
168000
CY2020 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
-164000
CY2020 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4110000
CY2020 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
5928000
CY2020 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
0
CY2020 us-gaap Stockholders Equity Other
StockholdersEquityOther
-6000
CY2020 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
6122000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
35194000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
277630000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
277630000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2021 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-9686000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7867000
CY2021 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
0
CY2021 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
978000
CY2021 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
98000
CY2021 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
18765000
CY2021 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
5572000
CY2021 usph Short Swing Profit Settlement
ShortSwingProfitSettlement
20000
CY2021 us-gaap Stockholders Equity Other
StockholdersEquityOther
1000
CY2021 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
5735000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
40831000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297181000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297181000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2022 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-2896000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7264000
CY2022 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
707000
CY2022 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
454000
CY2022 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
0
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
21321000
CY2022 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
5246000
CY2022 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
613000
CY2022 us-gaap Stockholders Equity Other
StockholdersEquityOther
695000
CY2022 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
4347000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
32158000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4004000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
317053000
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
4309000
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
5688000
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-258000
CY2022 usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
0
CY2021 usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
0
CY2020 usph Gain On Sale Of Partnership Interest Net Of Tax
GainOnSaleOfPartnershipInterestNetOfTax
1091000
CY2022 usph Derecognition Write Off Of Goodwill
DerecognitionWriteOffOfGoodwill
0
CY2021 usph Derecognition Write Off Of Goodwill
DerecognitionWriteOffOfGoodwill
0
CY2020 usph Derecognition Write Off Of Goodwill
DerecognitionWriteOffOfGoodwill
1859000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9112000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1175000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
112000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2022 us-gaap Payments For Proceeds From Limited Partnership
PaymentsForProceedsFromLimitedPartnership
-373000
CY2021 us-gaap Payments For Proceeds From Limited Partnership
PaymentsForProceedsFromLimitedPartnership
-275000
CY2020 us-gaap Payments For Proceeds From Limited Partnership
PaymentsForProceedsFromLimitedPartnership
-839000
CY2022 usph Proceeds From Sales Of Non Controlling Interest Permanent
ProceedsFromSalesOfNonControllingInterestPermanent
0
CY2021 usph Proceeds From Sales Of Non Controlling Interest Permanent
ProceedsFromSalesOfNonControllingInterestPermanent
131000
CY2020 usph Proceeds From Sales Of Non Controlling Interest Permanent
ProceedsFromSalesOfNonControllingInterestPermanent
0
CY2022 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
101000000
CY2021 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
316000000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
214000000
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1875000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1779000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2022 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0
CY2021 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0
CY2020 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
994000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022 usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
CY2022 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
3
CY2021 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
7
CY2022Q4 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
5
CY2022 usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
300000
CY2021Q4 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
2
CY2021 usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
100000
CY2020Q4 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
14
CY2020 usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
1100000
CY2020Q4 usph Cash Received Related To Sale Of Clinics
CashReceivedRelatedToSaleOfClinics
700000
CY2020Q4 usph Note Receivable Related To Sale Of Clinics
NoteReceivableRelatedToSaleOfClinics
400000
CY2020 usph Number Of Installments For Note Receivable In Sale Consideration
NumberOfInstallmentsForNoteReceivableInSaleConsideration
2
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022 usph Number Of Regions
NumberOfRegions
6
CY2022 usph Number Of Regions
NumberOfRegions
6
CY2021 usph Number Of Regions
NumberOfRegions
6
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
CY2022 usph Net Revenue From Medicare
NetRevenueFromMedicare
154900000
CY2021 usph Net Revenue From Medicare
NetRevenueFromMedicare
134400000
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
553144000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
495022000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
422969000
CY2021 usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.035
CY2022Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.0075
CY2021Q4 usph Percentage Of Reduction In Medicare Payments For Services Performed By A Physical Or Occupational Therapist
PercentageOfReductionInMedicarePaymentsForServicesPerformedByAPhysicalOrOccupationalTherapist
0.15
CY2022 usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
CY2022 usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
CY2013Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2027Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q2 usph Percentage Of Payment Reduction Waived Through Enacted Legislation
PercentageOfPaymentReductionWaivedThroughEnactedLegislation
0.02
CY2022 usph Extension Term For Sequester Relief Applied To All Medicare Payments
ExtensionTermForSequesterReliefAppliedToAllMedicarePayments
P3M
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period One
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodOne
0.02
CY2022Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2022 usph Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System
PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem
0.01
CY2022 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2022 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2022 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2022 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2022 usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
CY2022 usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
CY2022 usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
5400000
CY2021 us-gaap Unrealized Gain Loss On Interest Rate Cash Flow Hedges Pretax Accumulated Other Comprehensive Income Loss
UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss
4000000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
8300000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3500000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q4 usph Number Of Closed Clinics Sold
NumberOfClosedClinicsSold
14
CY2020 usph Aggregate Sale Price Of Cinics
AggregateSalePriceOfCinics
1100000
CY2020Q4 usph Cash Received Related To Sale Of Clinics
CashReceivedRelatedToSaleOfClinics
700000
CY2020Q4 usph Note Receivable Related To Sale Of Clinics
NoteReceivableRelatedToSaleOfClinics
400000
CY2020 usph Number Of Installments For Note Receivable In Sale Consideration
NumberOfInstallmentsForNoteReceivableInSaleConsideration
2
CY2022 us-gaap Net Income Loss
NetIncomeLoss
32158000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
40831000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
35194000
CY2022 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-3890000
CY2021 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-13011000
CY2020 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-4632000
CY2022 usph Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRate
0.2555
CY2022 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-994000
CY2021 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-3324000
CY2020 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-1216000
CY2022 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
29262000
CY2021 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
31144000
CY2020 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
31778000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.25
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.41
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.41
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.48
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.48
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12985000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12985000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12898000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12898000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12835000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12835000
CY2022 usph Number Of Partnership In Which Interest Acquired
NumberOfPartnershipInWhichInterestAcquired
3
CY2022 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
300000
CY2021 usph Number Of Partnership In Which Interest Acquired
NumberOfPartnershipInWhichInterestAcquired
5
CY2021 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
1300000
CY2021 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
100000
CY2020 usph Number Of Partnership In Which Interest Acquired
NumberOfPartnershipInWhichInterestAcquired
5
CY2020 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
300000
CY2020 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
100000
CY2021Q4 us-gaap Goodwill
Goodwill
434679000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
72674000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
89746000
CY2022 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-4140000
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-713000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9112000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q4 us-gaap Goodwill
Goodwill
494101000
CY2021Q4 us-gaap Goodwill
Goodwill
434679000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9100000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
108755000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
86382000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6523000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3698000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3414000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22912000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23569000
CY2022Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
8094000
CY2021Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
6649000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1666000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1984000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
243000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
498000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2716000
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
0
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
1000000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2021Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2750000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4498000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6539000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37413000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45705000
CY2022Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
2800000
CY2021 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
2600000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
185555000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1861000
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
183694000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
118417000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
0
CY2021Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
118417000
CY2022Q4 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
8271000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
408000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7863000
CY2021Q4 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
830000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
830000
CY2022Q4 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
177284000
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1453000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
175831000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
30710000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1049000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
117587000
CY2022 us-gaap Profit Loss
ProfitLoss
43407000
CY2021 us-gaap Profit Loss
ProfitLoss
57924000
CY2022 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
-5378000
CY2021 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
0
CY2022 usph Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRatePercent
0.2555
CY2022 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
1374000
CY2021 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
0
CY2022 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
47411000
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
57924000
CY2022 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
11249000
CY2021 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
17093000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36162000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
40831000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
35154000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
32021000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1160000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1454000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
6287000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
7057000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
5752000
CY2022 us-gaap Lease Cost
LeaseCost
42490000
CY2021 us-gaap Lease Cost
LeaseCost
40238000
CY2020 us-gaap Lease Cost
LeaseCost
37916000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
36136000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
33192000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
30307000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
40502000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
46088000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
32710000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
36409000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
29863000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
22020000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
14810000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
15318000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
118420000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6777000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
111643000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y21D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M1D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.029
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.028
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.031
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1464000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2817000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
605000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
573000
CY2022Q4 usph Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
28525000
CY2021Q4 usph Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
26856000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30594000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30246000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
23836000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
19607000
CY2022Q4 usph Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
26318000
CY2021Q4 usph Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
24637000
CY2022Q4 usph Deferred Tax Liabilities Gain On Cash Flow Hedge
DeferredTaxLiabilitiesGainOnCashFlowHedge
1373000
CY2021Q4 usph Deferred Tax Liabilities Gain On Cash Flow Hedge
DeferredTaxLiabilitiesGainOnCashFlowHedge
0
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
370000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
387000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
51897000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
44631000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
21303000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
14385000
CY2022Q4 usph Deferred Tax Assets Related To Redeemable Non Controlling Interests And Acquisitions Of Non Controlling Interests
DeferredTaxAssetsRelatedToRedeemableNonControllingInterestsAndAcquisitionsOfNonControllingInterests
400000
CY2022 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
300000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
9307000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
11782000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
10125000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2079000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2478000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1956000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2022 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction Amount
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeductionAmount
-149000
CY2022 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeduction
-0.003
CY2021 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction Amount
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeductionAmount
246000
CY2021 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeduction
0.004
CY2020 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction Amount
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeductionAmount
99000
CY2020 usph Effective Income Tax Rate Reconciliation Shortfall Excess Equity Compensation Deduction
EffectiveIncomeTaxRateReconciliationShortfallExcessEquityCompensationDeduction
-0
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
629000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.014
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1258000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.022
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1040000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.021
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12164000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.274
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15272000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.272
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13022000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.27
CY2020Q4 us-gaap Assets
Assets
594361000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-770000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
7477000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
10506000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
518000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2107000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2774000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-252000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9584000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
13280000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
9933000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
4866000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-38000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
2483000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
822000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-220000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
12416000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5688000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-258000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12164000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15272000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13022000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Revenues
Revenues
553144000
CY2021 us-gaap Revenues
Revenues
495022000
CY2020 us-gaap Revenues
Revenues
422969000
CY2022 us-gaap Gross Profit
GrossProfit
112024000
CY2021 us-gaap Gross Profit
GrossProfit
117182000
CY2020 us-gaap Gross Profit
GrossProfit
94450000
CY2022Q4 us-gaap Assets
Assets
858154000
CY2021Q4 us-gaap Assets
Assets
749426000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3200000
CY2022Q4 usph Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Grants For The Cumulative Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockGrantsForTheCumulativePeriod
1674423
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2022Q4 usph Share Based Compensation Arrangement By Share Based Payment Award Options Exercises For The Cumulative Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesForTheCumulativePeriod
918091
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
582491
CY2022Q4 usph Share Based Compensation Arrangement By Share Based Payment Award For Shares Outstanding Restrictions Had Not Lapsed
ShareBasedCompensationArrangementByShareBasedPaymentAwardForSharesOutstandingRestrictionsHadNotLapsed
124939
CY2021Q4 usph Share Based Compensation Arrangement By Share Based Payment Award For Shares Outstanding Restrictions Had Not Lapsed
ShareBasedCompensationArrangementByShareBasedPaymentAwardForSharesOutstandingRestrictionsHadNotLapsed
102682
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
CY2022 usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
185117
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
81.03
CY2021 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2022 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2022 usph Defined Contribution Plan Period For New Employees Covered Under Plan
DefinedContributionPlanPeriodForNewEmployeesCoveredUnderPlan
P3M
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022 usph Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
2000000
CY2021 usph Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
1900000
CY2020 usph Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
1900000
CY2022 usph Employment Agreement Term
EmploymentAgreementTerm
P2Y
CY2022 usph Renewal Period For Employment Agreement
RenewalPeriodForEmploymentAgreement
P2Y
CY2022Q4 usph Employee Compensation Future Payment Due Next Fiscal Year
EmployeeCompensationFuturePaymentDueNextFiscalYear
58600000
CY2022Q4 usph Employee Compensation Future Payment Due Next Fiscal Year Thereafter
EmployeeCompensationFuturePaymentDueNextFiscalYearThereafter
5700000
CY2021 usph Short Swing Profit Settlement
ShortSwingProfitSettlement
20000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-23-009198-index-headers.html Edgar Link pending
0001140361-23-009198-index.html Edgar Link pending
0001140361-23-009198.txt Edgar Link pending
0001140361-23-009198-xbrl.zip Edgar Link pending
brhc10048514_10k.htm Edgar Link pending
brhc10048514_ex21-1.htm Edgar Link pending
brhc10048514_ex23-1.htm Edgar Link pending
brhc10048514_ex31-1.htm Edgar Link pending
brhc10048514_ex31-2.htm Edgar Link pending
brhc10048514_ex32-1.htm Edgar Link pending
brhc10048514_ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
brhc10048514_10k_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20221231.xsd Edgar Link pending
usph-20221231_cal.xml Edgar Link unprocessable
usph-20221231_def.xml Edgar Link unprocessable
usph-20221231_pre.xml Edgar Link unprocessable
usph-20221231_lab.xml Edgar Link unprocessable